Alzheimer's drugs how is it treated ?

One of the most important worldwide challenges are the next generation Alzheimer's disease treatments. New results, candidate therapeutics, and methodological issues will be some of the major worldwide issues discussed at the 2019 CTAD Congress. It will also allow the participants to share their experience on the disease symptoms, and their skills on the dementia treatment. New goals for the Alzheimer's disease treatments are to identify the new biomarkers as well as more sensitive clinical assessment tools in order to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. The AD disease process can be minored thanks to non-pharmaceutical trials and that anti-amyloid treatment, as discussed at the 2018 CTAD Congress. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. The CTAD 2019 Congress will highlight the latest on trying to get these trials off the ground. Speeding the development of effective Alzheimer's treatment disease is one of the urge of the CTAD 2019 conference. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.